Fierce Biotech December 18, 2023
Even after decades of experience developing eye-related devices under its belt, Carl Zeiss Meditec is still looking to expand its ophthalmic portfolio.
The German company—a subsidiary of the larger Zeiss Group conglomerate—announced Friday that it has inked an agreement to acquire Dutch Ophthalmic Research Center, or DORC, a research institute in the Netherlands that is churning out a line of retinal surgical devices.
Under the terms of their agreement, Zeiss will buy out 100% of DORC’s shares from the institute’s current owner, the French investment firm Eurazeo. All told, the acquisition is valued at approximately 985 million euros, or about $1.08 billion, according to the announcement.
Though the deal is still in need of certain regulatory and antitrust sign-offs, Zeiss...
Today's Sponsors
Today's Sponsor